Looking for Sentiment Analysis? Discover the most popular stocks on Reddit by using our Sentiment Tracker
Market Cap 78.06M P/E - EPS this Y 36.50% Ern Qtrly Grth -
Income -164.57M Forward P/E -0.79 EPS next Y 9.50% 50D Avg Chg 11.00%
Sales 9.94M PEG - EPS past 5Y - 200D Avg Chg 4.00%
Dividend N/A Price/Book 0.72 EPS next 5Y - 52W High Chg -66.00%
Recommedations 2.00 Quick Ratio 3.80 Shares Outstanding 26.45M 52W Low Chg 57.00%
Insider Own 1.08% ROA -38.32% Shares Float 11.26M Beta 1.78
Inst Own 81.50% ROE -227.95% Shares Shorted/Prior 1.82M/1.32M Price 3.79
Gross Margin - Profit Margin - Avg. Volume 74,632 Target Price 19.25
Oper. Margin -6,996.11% Earnings Date May 8 Volume 39,194 Change -3.81%
About Syros Pharmaceuticals, Inc.

Syros Pharmaceuticals, Inc., a biopharmaceutical company, focuses on the development of treatment for hematologic malignancies. The company's lead product candidates are Tamibarotene, a selective retinoic acid receptor alpha agonist, which is in Phase III clinical trial for genomically defined subset of patients with myelodysplastic syndrome and Phase II clinical trial for patients with acute myeloid leukemia; SY-2101, a novel oral form of arsenic trioxide for treating patients with acute promyelocytic leukemia; and SY-5609, a cyclin-dependent kinase 7 inhibitor, which is in a Phase I clinical trial in patients with select advanced solid tumors. The company was formerly known as LS22, Inc. and changed its name to Syros Pharmaceuticals, Inc. in August 2012. Syros Pharmaceuticals, Inc. was incorporated in 2011 and is headquartered in Cambridge, Massachusetts.

Syros Pharmaceuticals, Inc. News
04/12/24 The Zacks Analyst Blog Highlights Bristol Myers, Moderna, 2seventy bio, Amylyx Pharmaceuticals and Syros Pharmaceuticals
04/10/24 Syros (SYRS) Up on FDA Fast Track Tag for Tamibarotene in AML
04/10/24 Syros Pharmaceuticals (SYRS) Soars 22.2%: Is Further Upside Left in the Stock?
04/09/24 Syros Receives Fast Track Designation from the FDA for Tamibarotene for the Treatment of Newly Diagnosed Unfit AML with RARA gene overexpression
04/02/24 Syros Reports Inducement Grants Under Nasdaq Listing Rule 5635(c)(4)
03/28/24 Syros Pharmaceuticals, Inc. (NASDAQ:SYRS) Q4 2023 Earnings Call Transcript
03/28/24 Syros Pharmaceuticals Full Year 2023 Earnings: Misses Expectations
03/27/24 Syros Reports Fourth Quarter and Full Year 2023 Financial Results and Provides a Corporate Update
03/25/24 Syros Announces Completion of Enrollment of 190 Patients Necessary to Support Primary Endpoint Analysis in SELECT-MDS-1 Phase 3 Trial
03/20/24 Syros to Report Fourth Quarter and Full Year 2023 Financial Results on Wednesday, March 27, 2024
02/27/24 Syros to Participate in TD Cowen 44th Annual Health Care Conference
02/27/24 Investors in Syros Pharmaceuticals (NASDAQ:SYRS) have seen respectable returns of 99% over the past year
01/31/24 3 Once-in-a-Lifetime Penny Stocks With Unprecedented Surge Potential
10:43 AM Syros (SYRS) Stock Surges 200% in 3 Months: Here's Why
01/18/24 Are You Looking for a Top Momentum Pick? Why Syros Pharmaceuticals, Inc. (SYRS) is a Great Choice
01/17/24 Syros Pharmaceuticals, Inc. (SYRS) Is a Great Choice for 'Trend' Investors, Here's Why
01/16/24 What Makes Syros Pharmaceuticals, Inc. (SYRS) a New Buy Stock
01/16/24 Wall Street Analysts Predict a 199.31% Upside in Syros Pharmaceuticals, Inc. (SYRS): Here's What You Should Know
01/11/24 Why Syros Pharmaceuticals (SYRS) Stock Might be a Great Pick
01/08/24 Syros Highlights Anticipated 2024 Milestones to Deliver on the Value of Tamibarotene
SYRS Chatroom

User Image Slowgallop Posted - 12 hours ago

$SYRS Please don't panic. Investors are intermittently moving to other stocks with more "imminent" catalysts like SLS, et al. will return as SYRS approaches FDA approval... Keeping "foot-in-the-door" positions in the meantime...SYRS has a meeting with destiny! 😊

User Image Ashsol7 Posted - 12 hours ago

$SYRS trash

User Image Ashsol7 Posted - 12 hours ago

$SYRS going back to 0

User Image lucabrix Posted - 1 day ago

$SYRS hits LTL, now I hope for a reversal!

User Image Ashsol7 Posted - 1 day ago

$SYRS this is only going down im glad i sold again few days ago, will buy back under $3

User Image DharlMorey2 Posted - 1 day ago

$SYRS Buying on any dip under 6.00 these days -- I think this will push to 20+ during Q3/Q4 data release

User Image RallyRaider Posted - 3 days ago

$SYRS holding up very nicely! great volume bar off the bottom dank institutions loaded the boat...

User Image Ashsol7 Posted - 4 days ago

$SYRS with war and bad economy this is hoing back to around 2$

User Image Ashsol7 Posted - 1 week ago

$SYRS its so annoying it goes up during day and after market it crashes, lets go 6$ already

User Image FutureIsOurs5 Posted - 1 week ago

$SYRS

User Image RallyRaider Posted - 1 week ago

$SYRS they are serious about this turnaround?

User Image Ithaca2018 Posted - 1 week ago

$SYRS Why is our sentiment bearish? I'm not feeling that at all!

User Image RonFarms Posted - 1 week ago

$SYRS good news!

User Image History101 Posted - 1 week ago

$SYRS 2,679 watching 4/10/2024

User Image Ashsol7 Posted - 1 week ago

$SYRS how can this be down after FDA? lets go 8$ today

User Image lucabrix Posted - 1 week ago

$SYRS Reply!

User Image DharlMorey2 Posted - 1 week ago

$ATOS Saw the same thing on my $SYRS where it took 2 days for tutes to process the news before a 300% gain. The BIG news: "Atossa Therapeutics Presents Data from 40mg Cohort of Phase 2 EVANGELINE Clinical Trial Showing 100% Disease Control Rate After 24-Weeks of Treatment with (Z)-Endoxifen" ASCO participation is only 14 days away (11 trading days) -- so we're going to know very quickly how big the next round of fireworks are :) May 24th we get the text -- and then a week later Russell 2000/3000 preliminary lists are released -- we may see some serious volume. The news source: https://investors.atossatherapeutics.com/news-releases/news-release-details/atossa-therapeutics-presents-data-40mg-cohort-phase-2-evangeline $XBI $AMAM

User Image Peterpaypaul Posted - 1 week ago

$SYRS Very nice price action and good follow through..... 😊

User Image dnice22 Posted - 1 week ago

$SYRS pump and dump

User Image Bigeyes2 Posted - 1 week ago

$SYRS Swing

User Image Ithaca2018 Posted - 1 week ago

$SYRS Holding for the real juice:)

User Image RiskitfortheBiscuits Posted - 1 week ago

$SYRS ended up being a boring b day

User Image Byzantinos Posted - 1 week ago

$SYRS I called the fast track designation a few days ago but so far this is following similar pattern to 1/23 fast track for MDS. Guess we might just need full approval for the real juice.

User Image tradingtwenty Posted - 1 week ago

$SYRS has trended 18 times in the past 24 hours (based on 5 minute intervals). Latest press release on Apr 09, 2024 07:00 AM: Syros Receives Fast Track Designation from the FDA for Tamibarotene for the Treatment of Newly Diagnosed Unfit AML... Link: https://tradingtwenty.com/news/423463/syros-receives-fast-track-designation-from-the-fda-for-tamibarotene-for-the-treatment-of-newly-diagnosed-unfit-aml-with-rara-gene-overexpression

User Image _StockTrader Posted - 1 week ago

Real-Time Stock Data $SYRS Price: 5.58 Volume: 691060 Market Cap: 143817056 PE Ratio: -1.6556888 Powered by: AITX

User Image FutureIsOurs5 Posted - 1 week ago

$SYRS

User Image bogwalk Posted - 1 week ago

$SYRS

User Image VrtcIl Posted - 1 week ago

Let's get that 6 on $SYRS. However, make sure to keep stop set and always protect your downside. Never blindly keep on holding, let the market dictate your decisions. Price: 5.76 Float: 16.5M Short Float: 9.4 % 💰 Dollar Volume: 53.3K ℹī¸ USA | Biotechnology

User Image bogwalk Posted - 1 week ago

$SYRS

User Image RallyRaider Posted - 1 week ago

$SYRS thats how they leave you wondering. need a sign or two more here.

Analyst Ratings
Piper Sandler Overweight Apr 3, 24
HC Wainwright & Co. Buy Apr 1, 24
Piper Sandler Overweight Oct 3, 23
HC Wainwright & Co. Buy Aug 9, 23
HC Wainwright & Co. Buy May 11, 23
JMP Securities Market Outperform May 11, 23
Oppenheimer Outperform Mar 3, 23
HC Wainwright & Co. Buy Mar 3, 23
Piper Sandler Overweight Jan 5, 23
Insider Trades Relationship Date Transactions Cost($) #Shares Value($) #Share Own SEC Form 4
AKKARAJU SRINIVAS Director Director Dec 21 Buy 4.42 904,977 3,999,998 1,786,427 12/26/23
Olson Eric R Chief Scientific Off.. Chief Scientific Officer Jul 17 Sell 3.50 689 2,412 6,661 07/18/23
Young Richard A Director Director Feb 10 Sell 8.87 5,990 53,131 329,211 02/10/21
Simonian Nancy A President & CEO President & CEO Dec 21 Option 7.21 29,917 215,702 563,606 12/21/20
Young Richard A Director Director Nov 18 Sell 8.87 5,990 53,131 339,211 11/18/20